Outcome of Board Meeting_Change in Directors

Biocon's Board meeting on May 7, 2026 approved multiple significant items. Key decisions include: (1) Audited FY2026 financial results with March 31, 2026 year-end, (2) Recommended final dividend of Rs. 0.50 per share (10%) for FY2026 payable by August 31, 2026, subject to shareholder approval, (3) Change in statutory auditors from B S R & Co. LLP to S. R. Batliboi & Associates LLP for 5 years from the 48th AGM, (4) Designation of Dr. Anuj Goel as Chief Development Officer and Mr. Susheel Umesh as Chief Commercial Officer – Emerging Markets as Senior Management Personnel, (5) Appointment of 6 new directors including 5 Independent Directors (Rajiv Malik, Daniel Bradbury, Peter Piot, Arun Chandavarkar, Nivruti Rai) and 1 Non-Executive Non-Independent Director (Thomas Jason Roberts), plus re-appointment of Rekha Mehrotra Menon as Independent Director, all effective August 1, 2026, (6) Acquisition of remaining ~2% equity of Biocon Biologics Limited (BBL) through share swap of 87,92,317 Biocon shares worth Rs. 330.73 Crores at Rs. 376.16 per share, plus conversion of OCDs and CCDs into BBL equity, taking Biocon's stake to ~99.99%, and (7) Approval of Biocon Unity Long Term Incentive Plan 2026.